chondroitin-sulfates and Back-Pain

Topics: Back Pain; Balneology; Chondroitin Sulfates; Combined Modality Therapy; Humans; Intervertebral Disc; Nerve Compression Syndromes; Osteochondritis; Papain; Peripheral Nervous System Diseases; Radiography; Spinal Diseases

To study the efficacy and safety of chondroitin sulfate (mucosat) in the treatment of chronic lower back pain.. The medical documentation of 46 outpatients with chronic lumbosacral dorsalgia, who received 25 intramuscular injections of 2 ml mucosat, was studied. The assessment of patients' condition and efficacy and safety of the treatment was conducted based on the data of four visits (1-st, 10-th and 25-th day and 3 months after the end of treatment). Results of the clinical-neurological examination, pain intensity at rest and at movement according to the Visual Analogue Scale (VAS) and the severity of Lasegue and Wasserman signs and limitation of movements in the lumbar spine were taken into account.. The use of mucosat at a dose of 2 ml intramuscularly 1 time in 2 days led to a significant decrease in the severity of pain syndrome and increased mobility in the lumbar spine (before treatment, the level of pain at rest according to the VAS was 4.22±1.28 scores, on the 25-th day 2.13±0.24, 3 month after treatment 2.37±0.31; the level of pain at movement: 5.78±1.15; 4.56±0.47; 4.78±0.22, respectively (p<0.01). There were a reduction of the dose of previously used non-steroidal anti-inflammatory drugs in the end of treatment and maintenance of the results of therapy for 3 months after the end of treatment. Good tolerability of the drug and the absence of significant side-effects were shown as well.. This study showed the efficacy and safety of chondroitin sulfate (mucosat) in the treatment of outpatients with chronic lower back pain.. Цель исследования. Определение эффективности и безопасности применения хондроитина сульфата (мукосат) в терапии хронической боли в нижней части спины. Материал и методы. Изучена медицинская документация 46 пациентов с хронической пояснично-крестцовой дорсалгией, получивших в условиях поликлиники курс 25 внутримышечных инъекций 2 мл препарата 'Мукосат'. Оценку состояния больных, эффективности и безопасности лечения проводили, исходя из информации, полученной в ходе четырех визитов (на 1, 10 и 25-й день терапии и через 3 мес после окончания курса лечения). Учитывали данные клинико-неврологического обследования, оценку интенсивности боли в покое и при движении по визуально-аналоговой шкале (ВАШ), выраженность симптомов Ласега и Вассермана, степень ограничения подвижности в поясничном отделе позвоночника. Результаты. Применение мукосата привело к достоверному снижению выраженности болевого синдрома. Уровень боли в покое по шкале ВАШ до лечения составлял 4,22±1,28 балла, на 25-й день терапии - 2,13±0,24 балла, через 3 мес после окончания курса лечения - 2,37±0,31 балла; уровень боли при движении - 5,78±1,15, 4,56±0,47 и 4,78±0,22 балла соответственно (р<0,01). Также были отмечены увеличение подвижности в поясничном отделе позвоночника, сокращение дозы ранее применяемых нестероидных противовоспалительных препаратов к концу курса лечения и сохранение результатов терапии через 3 мес после окончания курса лечения. Проведенный курс лечения показал хорошую переносимость препарата и отсутствие значимых побочных эффектов. Заключение. Результаты исследования свидетельствуют об эффективности и безопасности хондроитина сульфата (мукосат) в терапии амбулаторных пациентов с хроническим болевым синдромом в нижней части спины.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Chondroitin Sulfates; Humans; Low Back Pain; Lumbar Vertebrae; Treatment Outcome

The article deals with various aspects of pain in degenerative diseases of the spine and with the actual problems of non-specific back pain. The data on the mechanisms of pain and analgesic treatment algorithms of the patients with radicular syndrome, and pharmacological and non-pharmacological therapies is provided. The effect of structural-modifying drugs in relief of nonspecific back pain was investigated and compared with a traditional nonsteroidal anti-inflammatory drug (NSAID) therapy in combination with B vitamins, without chondroprotectors. The study population was composed of 85 patients (42 men and 43 women) aged 38 to 68 years (mean age - (46,3±2,6) years) with chronic vertebral pain syndromes (VPS). For objectification assessment of pain, severity of pain, and evaluate the effectiveness of therapy we used the visual analog scale (VAS).The majority (88%) of the patients included in the study, complained of a moderately severe pain (from 40 to 70 mm on the VAS). Patients were divided into two groups. The first (primary) group consisted of 55 patients (30 men and 25 women). The following treatment was applied: all patients of the first group, in addition to the NSAID administered with hondroprotektror arbitrarily - Struktum 1000 mg twice a day or 300 mg Piaskledin once a day for 40-60 days.The second (control) group consisted of 30 patients (14 men, 16 women). Patients in the control group administered with a traditional NSAID therapy in combination with B vitamins, without chondroprotectors. The results of the study on the influence of drugs Piaskledin 300, Struktum for the relief of nonspecific back pain revealed that in the treatment of vertebral pain, a combination of non-steroidal anti-inflammatory drugs with structure-modifying agents could achieve rapid rehabilitation of patients with locomotor activity and improve quality of life in general.

Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Case-Control Studies; Chondroitin Sulfates; Female; Humans; Male; Middle Aged; Plant Oils